Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AcelRx Pharmaceuticals Inc.

www.acelrx.com

Latest From AcelRx Pharmaceuticals Inc.

2018 Complete Response Letters: Efficacy Issues Drove Most Product Rejections

US FDA issued at least seven rejections to novel products; opioid analgesic sponsors had very little success, while biosimilar developers had a so-so year.

Complete Response Letters Drug Review

Opioid Sponsors Enter 2019 At A Crossroads

Recent regulatory trends at US FDA offer no clear path to success for sponsors developing opioids. As 2018 concludes with only one approval and at least five rejections, firms will need new strategies if they hope to bring the analgesics to market. 
Research & Development Neurology

Keeping Track: FDA Clears Motegrity And Second Herceptin Biosimilar, But Rebuffs SpecGx's Oxycodone

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Pain Therapeutics Appeals Remoxy CRL In Likely Last Ditch Effort To Save Abuse-Deterrent Opioid

Meeting with US FDA in January will aim to reverse fourth rejection in 10 years; firm still criticizing agency even as it works to reconcile their positions.
Complete Response Letters Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • SuRx Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AcelRx Pharmaceuticals Inc.
  • Senior Management
  • Vincent J Angotti, CEO
    Raffi Asadorian, CFO
    Larry G Hamel, Chief Dev. Officer
    Pamela P Palmer, MD, PhD, CMO
    Mark A Evashenk, VP, Clinical Operations
    Kim Gaumer, VP, Reg. Affairs & Quality Assurance
  • Contact Info
  • AcelRx Pharmaceuticals Inc.
    Phone: (650) 216-3500
    351 Galveston Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register